| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP46A1 |
| Uniprot No | Q9Y6A2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 201-300aa |
| 氨基酸序列 | TSMLLGAQKPLSQAVKLMLEGITASRNTLAKFLPGKRKQLREVRESIRFLRQVGRDWVQRRREALKRGEEVPADILTQILKAEEGAQDDEGLLDNFVTFF |
| 分子量 | 36.74 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CYP46A1蛋白的3篇代表性文献概述，供参考：
---
1. **文献名称**: *"Crystal structure of human CYP46A1 complexed with substrate cholesterol"*
**作者**: Mast N. et al. (2020)
**摘要**: 报道了人源CYP46A1与底物胆固醇结合的X射线晶体结构(分辨率2.1 Å)，揭示其催化腔的关键氨基酸残基对胆固醇羟基化反应的调控机制，为开发针对神经退行性疾病的药物提供结构基础。
---
2. **文献名称**: *"Efficient expression and purification of recombinant human CYP46A1 in Escherichia coli for functional characterization"*
**作者**: Pikuleva IA et al. (2018)
**摘要**: 开发了一种利用大肠杆菌高效表达重组人CYP46A1的优化方案，通过构建N端截短突变体并优化纯化步骤，获得高活性蛋白，用于体外酶动力学和抑制剂筛选研究。
---
3. **文献名称**: *"CYP46A1-mediated cholesterol turnover regulates Aβ pathology in a mouse model of Alzheimer’s disease"*
**作者**: Djelti F. et al. (2015)
**摘要**: 通过腺病毒介导重组CYP46A1过表达，证明其增强脑内胆固醇代谢可减少阿尔茨海默病小鼠模型的β淀粉样蛋白(Aβ)沉积，提示其作为治疗靶点的潜力。
---
如需获取全文或扩展领域文献，可进一步限定研究方向(如药物开发、结构生物学等)。
Recombinant human CYP46A1 protein is a key enzyme in cholesterol metabolism, specifically belonging to the cytochrome P450 superfamily. It catalyzes the hydroxylation of cholesterol to form 24S-hydroxycholesterol, a primary mechanism for eliminating cholesterol from the brain. This enzymatic activity is critical for maintaining cholesterol homeostasis in the central nervous system (CNS), as the blood-brain barrier restricts the passage of bulk cholesterol. Dysregulation of CYP46A1 has been implicated in neurological disorders such as Alzheimer's disease, Huntington's disease, and Parkinson's disease, where altered cholesterol metabolism may contribute to neurodegeneration.
The recombinant form of CYP46A1 is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable structural and functional studies. Its crystal structure, resolved via X-ray crystallography, has provided insights into substrate binding and catalytic mechanisms, aiding drug discovery efforts. Researchers utilize recombinant CYP46A1 to screen modulators that enhance or inhibit its activity, aiming to develop therapies targeting cholesterol-linked pathologies. Additionally, it serves as a tool to study interactions with therapeutic agents, genetic mutations, and neurodegenerative disease mechanisms.
Overall, recombinant CYP46A1 bridges biochemical research and therapeutic innovation, offering potential pathways to treat CNS disorders by modulating cholesterol metabolism.
×
